• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NovoBioPharma partnership launches

NovoBioPharma partnership launches

June 12, 2013
CenterWatch Staff

NovoBioPharma, a partnership of experts collaborating with life science organizations to provide medical, scientific, regulatory, business and financial advisory services, has launched. The global business has four principals who have partnered to help life science companies and institutions advance drug, diagnostic and device candidates by leveraging opportunities from conception through clinical development and regulatory approval.

NovoBioPharma offers services in capital sourcing and management, business development, intellectual property, quality control, manufacturing, study design and protocol development. The four principals are Bernie Rudnick, M.B.A., chief business officer; Ira Wallace, M.D., M.B.A., chief development officer; Shahin Gharakhanian M.D., head of pharmaceutical medicine; and Andrew D. Luber, chief scientific officer.

Rudnick is founder and managing partner of CapGenic Advisors and a founding member of several angel investing groups; he has led capital formation of $530 million in the past 10 years and $3 billion during the last 15 years. Rudnick founded, managed and advised companies in the life sciences, including diagnostic, therapeutic and clinical software environments. 

Wallace has been involved in pharmaceutical, biotech and medical device companies as a chief executive officer, founder, board member and consultant. Wallace has experience in technology transfer and intellectual property strategies and is a founding member and partner in several angel investment groups.

Gharakhanian is an infectious diseases and internal medicine trained physician with 20 years of experience in the pharmaceutical industry and clinical practice. His was vice president in the medicines development group/global R&D at Vertex Pharmaceuticals. Gharakhanian has handled projects for 12 different pharmaceutical companies, 10 different brands and four drug launches in Asia, Canada, the E.U. and the U.S.

Luber is an infectious diseases trained clinical pharmacist/pharmacologist with 18 years of experience working with the pharmaceutical industry as an investigator, opinion leader, speakers’ bureau, steering committee and advisory board member. He has served as a clinical consultant to large and early stage pharmaceutical companies. Luber has been an investigator in more than 70 clinical trials including four phase Ia first-in-human studies and specializes in early stage drug development.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing